Clearside Biomedical Inc. (Nasdaq: CLSD) enrolled the first patient in a Phase 3 clinical trial of suprachoroidal CLS-TA to treat macular edema associated with Retinal Vein Occlusion. The stock price soared $2.62 to close at $12.95.
Clearside Biomedical enrolls first patient in study
March 06, 2018 at 16:26 PM EST
